文献速递眼底病与葡萄膜炎

雷珠单抗治疗初治新生血管性年龄相关性黄斑变性:LUMINOUS全球真实世界研究结果

RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study.
PubMed 文献 · Retina · 2020-01-01

1年平均视力提高3.1个字母,平均注射5.0次、监测8.8次;眼部/非眼部不良事件发生率8.2%/12.8%,严重不良事件0.9%/7.4%。结论表明雷珠单抗在初治患者中有效且安全。

要点

  • 初治新生血管性年龄相关性黄斑变性患者1年平均视力提高3.1个字母,基线视力51.9个字母(Snellen 20/92)。
  • 注射频率<3次、3至6次、>6次组视力提高分别为1.6、3.3、3.7个字母。
  • 基线视力<23、23至<39、39至<60、60至<74、≥74个字母组视力变化分别为12.6、6.7、3.6、0.3、-3.0个字母。

核心结论

  • 结果表明雷珠单抗在初治新生血管性年龄相关性黄斑变性患者中有效且安全。

主要发现

  • 初治患者基线平均(SD)年龄75.0(10.2)岁,女性54.9%,白人66.5%。
  • 1年平均(SD)视力提高3.1(16.51)个字母(n=3379;基线视力51.9个字母[Snellen 20/92]),平均(SD)注射5.0(2.7)次、监测8.8(3.3)次。
  • 注射频率<3次(n=537)、3至6次(n=1924)、>6次(n=918)组视力提高分别为1.6(14.93)、3.3(16.57)、3.7(17.21)个字母。
  • 基线视力<23(n=382)、23至<39(n=559)、39至<60(n=929)、60至<74(n=994)、≥74(n=515)个字母组视力变化分别为12.6(20.63)、6.7(17.88)、3.6(16.41)、0.3(13.83)、-3.0(11.82)个字母。
  • 眼部/非眼部不良事件发生率为8.2%/12.8%,严重不良事件为0.9%/7.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in treatment-naive patients with neovascular age-related macular degeneration enrolled in LUMINOUS study. METHODS: This 5-year, prospective, multicenter, observational study recruited 30,138 adult patients (treatment-naive or previously treated with ranibizumab or other ocular treatments) who were treated according to the local ranibizumab label. RESULTS: Six thousand two hundred and forty-one treatment-naive neovascular age-related macular degeneration patients were recruited. Baseline (BL) demographics were, mean (SD) age 75.0 (10.2) years, 54.9% females, and 66.5% Caucasian. The mean (SD) visual acuity (VA; letters) gain at 1 year was 3.1 (16.51) (n = 3,379; BLVA, 51.9 letters [Snellen: 20/92]) with a mean (SD) of 5.0 (2.7) injections and 8.8 (3.3) monitoring visits. Presented by injection frequencies <3 (n = 537), 3 to 6 (n = 1,924), and >6 (n = 918), visual acuity gains were 1.6 (14.93), 3.3 (16.57), and 3.7 (17.21) letters, respectively. Stratified by BLVA <23 (n = 382), 23 to <39 (n = 559), 39 to <60 (n = 929), 60 to <74 (n = 994), and ≥74 (n = 515), visual acuity change was 12.6 (20.63), 6.7 (17.88), 3.6 (16.41), 0.3 (13.83), and -3.0 (11.82) letters, respectively. The incidence of ocular/nonocular adverse events was 8.2%/12.8% and serious adverse events were 0.9%/7.4%, respectively. CONCLUSION: These results demonstrate the effectiveness and safety of ranibizumab in treatment-naive neovascular age-related macular degeneration patients.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Holz FG, Figueroa MS, Bandello F, et al. RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study. Retina. 2020. PMID: 31764612. doi:10.1097/IAE.0000000000002670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。